Skip navigation
Skip navigation

Menopausal hormone therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales cancer lifestyle and evaluation of risk (CLEAR) study

Salagame, Usha; Banks, Emily; O'Connell, Dianne; Egger, Sam; Canfell, Karen


Breast cancer risk is increased with current Menopausal Hormone Therapy (MHT) use, with higher risks reported for ER+ (Estrogen Receptor positive), and ER+/PR+ (Estrogen and Progesterone Receptor positive) breast cancers than those of ER- and ER-/PR- status, respectively. There is limited evidence to suggest MHT use is associated with the specific subtype characterised as ER+/PR+/HER2- (Estrogen and Progesterone Receptor positive and Human Epidermal growth factor Receptor2 negative) status....[Show more]

CollectionsANU Research Publications
Date published: 2018
Type: Journal article
Source: PLOS ONE
DOI: 10.1371/journal.pone.0205034
Access Rights: Open Access


File Description SizeFormat Image
01_Salagame_Menopausal_hormone_therapy_use_2018.pdf1.02 MBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator